Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the…
|
L’associazione bendamustina più rituximab in pazienti con linfoma non-hodgkin
Quelli che… la Farmacia I risultati di uno studio, pubblicato su “The Lancet”, dimostrano che l’associazione bendamustina più rituximab (B-R) in pazienti con linfoma non-Hodgkin indolente e mantellare raddoppia la sopravvivenza libera da progressione di malattia (PFS … |
Engineering Stream Conferences at PEGS 2013PR Newswire (press release)FARMINGTON, Conn., March 13, 2013 /PRNewswire-iReach/ — Tools for engineering the next generation of antibodies and biologics will need to address the current challenges facing the …
Exciting Developments in Lymphoma (Lymphnode Cancer) and Myeloma …EIN News (press release)To date, up to 80% of patients with the most common subtype of malignant lymphoma (diffuse large B-cell lymphoma), are cured of this aggressive disease by chemo…
|
Evolution in the Antibody Factory: How Immune Cells Are Able to Advance Their …
Science Daily (press release) 11, 2013 — Immune system B cells play a crucial role in the defence of pathogens; when they detect such an intruder, they produce antibodies that help to combat the enemy. They concurrently and continuously improve these molecules to more precisely … |
Spectrum Pharmaceuticals Provides Update; Guides 2013 Revenue $160-180MBenzingaThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a tar…
Spectrum Pharmaceuticals Provides Corporate UpdateMarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targe…
ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD …PipelineReview.com (press release)HACKENSACK, NJ, USA I March 7, 2013 I ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and inte…
 PR Web (press release) |
MS Patient Website to Provide Most Extensive On-Site Coverage at AAN
PR Web (press release) “We’re expecting updates of important trials of oral drugs such as Gilenya, Aubagio and BG-12, as well as the infusion drugs such as Tysabri, alemtuzumab and daclizumab. This information is vital to help people make informed decisions about their … |
 Healio |
R-BAC shows promise in mantle cell lymphoma
Healio Combination therapy with cytarabine, bendamustine and rituximab was associated with strong response-related outcomes in mantle cell lymphoma, according to results of a phase 2 study. The researchers investigated the R-BAC combination — cytarabine, … |